Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More


Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

Study identifier: NCT01017640
Full study details on

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)


  • Solid tumor for which no curative or standard therapy exists or is no longer effective, tumor demonstrates deficiency in the Fanconi anemia pathway
  • prior PARP inhibitor treatment allow if used as a single agent
  • Up to two chemotherapy regimens for metastatic disease are allowed; in addition, prior adjuvant/neo- adjuvant chemotherapy, hormonal therapy, molecular targeted therapy or Erb inhibitor treatments (e.g., erlotinib, herceptin, sorafenib, sunitinib) will be allowed and will not count towards eligibility

Type of study:

Phase I study


Participants assigned to one of two groups:

  • Oral veliparib daily
  • 28 day cycles with mitomycin C intravenously on day 1 and oral veliparib on either days 1-7, 1-14, 1-21, or 1-28

Study sites:

District of Columbia
District of Columbia
Lombardi Comprehensive Cancer Center at Georgetown University
Contact: John L. Marshall 202-687-6459

Ohio State University Medical Center
Contact: Miguel A. Villalona-Calero 614-293-9424

Page updated 06/14/13

FORCE:Facing Our Risk of Cancer Empowered